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S U M M A R Y
Background: Healthcare-associated infections are a worldwide threat to hospitalized patients, especially
those in intensive care units. The prevalence of these infections in Egypt, and their antimicrobial
resistance patterns and mechanisms, were investigated in this study.
Methods: A total of 547 cases of healthcare-associated infections were investigated. Causative agents
were identiﬁed and antimicrobial susceptibility determined. Carbapenem-resistant Acinetobacter
baumannii isolates were further investigated for their resistance mechanism via the modiﬁed Hodge
test, inhibitor-potentiated disk diffusion test, synergy with carbonyl cyanide chlorophenylhydrazone,
and PCR. Moreover, clonal linkage was examined via enterobacterial repetitive intergenic consensus
(ERIC)-PCR.
Results: Klebsiella spp was the most prevalent species in the isolates examined (217; 40%). Although A.
baumannii represented only 10% of the total isolates, it showed the highest percentage of carbapenem
resistance (74%). PCR showed that 100% of the resistant isolates carried both blaOXA-51 and blaOXA-23
genes, 85% carried the class 1 integrase genes, and only 2.5% carried metallo-beta-lactamase (blaVIM).
ERIC-PCR indicated that isolates from different hospitals were genetically linked.
Conclusions: These ﬁndings represent the ﬁrst report of the alarming spread of OXA-23 carbapenemase
in A. baumannii in Egyptian intensive care units. The spread of such strains has serious health
consequences and requires the application of strict infection control measures.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Healthcare-associated infections (HAIs) occur worldwide, with
signiﬁcant economic costs and mortality. For decades, Gram-
negative bacilli (GNB) have maintained their share of HAIs;
however Acinetobacter are the only GNB associated with
consistently increasing proportions of HAIs. Acinetobacter bau-
mannii is predicted to become a predominant cause of HAIs due to
the selective pressure from antimicrobials in intensive care units
(ICUs), in addition to its incredible ability to acquire resistance.1
In the hospital setting, carbapenems, such as imipenem, are
reserved for the treatment of the most severely ill patients due to
their high potency, broad-spectrum activity, and good safety
proﬁle.2 In this study, the prevalence of Gram-negative rods
causing HAIs was investigated in three Egyptian ICUs. A. baumannii
showed the highest percentages of carbapenem resistance. The* Corresponding author. Tel.: +20 10 65344060; fax: +20 (0)2 23628246.
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http://dx.doi.org/10.1016/j.ijid.2013.07.012mechanism of resistance and clonal relatedness were further
studied.
2. Methods
A total of 547 HAIs in three ICUs were investigated in the period
between January 2011 and September 2012. The three hospitals
were: hospital A, 6th October Hospital (13 ICU beds); hospital B,
MUST Hospital (seven ICU beds); and hospital C, National Cancer
Institute (12 ICU beds). Only cases conﬁrmed to be HAIs (i.e.,
infection was ﬁrst present on or after the third hospital day) were
included.
Antimicrobial susceptibility and minimum inhibitory concen-
tration (MIC) testing were done using standard protocols.3
Evaluation of the molecular mechanisms of carbapenem resistance
in the carbapenem-resistant A. baumannii (CRAB) isolates was
performed using standard assays, such as the modiﬁed Hodge test,
inhibitor-potentiated disk diffusion (IPD), effect of the efﬂux pump
inhibitor carbonyl cyanide chlorophenylhydrazone (CCCP), and
PCR detection of blaOXA-51-like, blaOXA-23-like, and class 1 integrase
(int1) genes, as reviewed by Durante-Mangoni and Zarrilli.4 Finally,ses. Published by Elsevier Ltd. All rights reserved.
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enterobacterial repetitive intergenic consensus (ERIC)-PCR.
3. Results and discussion
A total of 547 non-duplicate GNB were recovered from the three
hospitals. The majority of infections were due to Klebsiella spp; the
frequencies of isolation of the different species and types of
infections associated with each species are summarized in Table 1.Table 1
Distribution of bacterial species causing different types of infections included in the st
UTI, n (%) RTI, n (%) Wound infecti
Acinetobacter baumannii 6 (11) 24 (45) 22 (42) 
Escherichia coli 36 (35) 19 (18) 44 (43) 
Enterobacter spp 1 (11 1 (11) 5 (56) 
Klebsiella spp 41 (19) 71 (33) 94 (43) 
Proteus spp 10 (67) - 5 (33) 
Pseudomonas spp 24 (16) 37 (25) 86 (57) 
Total 118 (21.6) 152 (27.8) 256 (46.8) 
UTI, urinary tract infections; RTI, respiratory tract infections.
Figure 1. DNA agarose gel showing the products of the ERIC-PCR on the Acinetobacter bau
(C) Dendrogram representing genetic relationships between A. baumannii isolates based
i.e., for isolates obtained from hospital A, the label starts with the letter A, etc.A. baumannii showed the highest imipenem resistance (74%).
With the exception of two recent studies,5,6 almost nothing is
known about A. baumannii resistance patterns in Egypt. For this
reason, all 39 CRAB isolates identiﬁed in this study were subjected
to further investigation. The former study (Al-Hassan et al.5)
included isolates from pediatric patients obtained from hospital C,
however the average age of our cases was 48.6 years.
Antimicrobial susceptibility testing showed that 100% of the
CRAB isolates were susceptible to colistin. However, the resistanceudy
ons, n (%) Bacteremia, n (%) Meningitis, n (%) Total, n (%)
1 (2) - 53 (10)
2 (2) 2 (2) 103 (19)
2 (22) - 9 (1.5)
9 (4) 2 (1) 217 (40)
- - 15 (2.5)
1 (1) 2 (1) 150 (27)
15 (2.7) 6 (1.1) 547 (100)
mannii carbapenem-resistant isolates from hospitals A and B (A), and hospital C (B).
 on ERIC-PCR ﬁngerprints. The isolates are labeled according to the source hospital,
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ceftazidime, cefepime, ciproﬂoxacin, and piperacillin/tazobactam,
and 80% or more to amikacin, aztreonam, gentamicin, and
tobramycin. The MIC values for imipenem were over 16 mg/ml
for 97.4% of the isolates, and 53.8% and 33.3% of the isolates had
values greater than 512 mg/ml for amikacin and gentamicin,
respectively. In accordance with previous ﬁndings, the respiratory
tract is the main site of infection and colistin is considered almost
the only treatment choice left for the management of A. baumannii
infections.
Phenotypic assays indicated that 82% of the CRAB isolates had
carbapenemase activity; 2.5% had metallo-beta-lactamase (MBL)
activity, and in no isolate did the overexpression of proton gradient-
dependent efﬂux pumps contribute to the observed resistance.
Multiplex PCR showed the presence of the blaOXA-51-like and the
blaOXA-23-like genes in all of the CRAB isolates. The blaVIM gene was
detected only in the isolate with MBL activity. OXA-23-type
carbapenemase-producing A. baumannii are becoming increasingly
widespread, with reports emerging from Europe, the USA,
Australia, Asia, Africa, and the Middle East.7
Integrase gene detection is considered a good marker for the
dissemination of epidemic Acinetobacter strains and it can be
responsible for the integration of resistance markers either in the
chromosome or plasmids.8 The int1 gene was detected in 85% of
our isolates, and PCR analysis indicated that blaOXA-23 was carried
on a plasmid in 28.2% of the CRAB isolates.
ERIC-PCR analysis revealed that 16 isolates – 13 from hospital A
and three from hospital B – showed identical patterns, however
those isolated from hospital C were unrelated to them, although
they showed closely related patterns amongst themselves
(Figure 1). This result indicates that clonal expansion of certain
CRAB is taking place in some of the Egyptian hospitals. PCR-based
ﬁngerprinting methods such as ERIC-PCR are simple, rapid, and
low-cost methods with high discrimination for the identiﬁcation
and differentiation of Acinetobacter spp.9 It has been concluded that
both pulsed ﬁeld gel electrophoresis (PFGE) and PCR-based
ﬁngerprinting are useful for typing Acinetobacter calcoaceticus–A.baumannii. However, PFGE can detect minor mutations in an
outbreak strain.10
Our results indicate that the observed imipenem resistance is
due to the spread of OXA-23-producing clones. The clinical
signiﬁcance of these isolates is of great concern as it emphasizes
the importance of having effective infection control measures in
Egyptian hospitals; strict adherence to these measures is required
to prevent the spread of these resistant organisms.
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